Results 161 to 170 of about 10,236,148 (357)

Data‐Driven Insights into Hyperkinetic Disorders in Neurodevelopmental Syndromes and Epileptic Encephalopathies

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Childhood‐onset hyperkinetic movement disorders occur in a range of genetic conditions. Recently, there has been an increase in recognition of hyperkinetic movement disorders, mainly dystonia, chorea and dyskinesia, with monogenic conditions associated with neurodevelopmental delay (NDD) and also with developmental and epileptic ...
Hugo Morales‐Briceño, Shekeeb S. Mohammad, Rajeshwar Reddy Angiti, Velda Han, Michel Tchan, Russell C. Dale, Victor S.C. Fung   +6 more
wiley   +1 more source

Lack of tolerance for the anti-dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats

Brazilian Journal of Medical and Biological Research, 2010
7-Nitroindazole (7-NI) inhibits neuronal nitric oxide synthase in vivo and reduces l-DOPA-induced dyskinesias in a rat model of parkinsonism. The aim of the present study was to determine if the anti-dyskinetic effect of 7-NI was subject to tolerance ...
N. Novaretti, F.E. Padovan-Neto, V. Tumas, C.A. da-Silva, E.A. Del Bel   +4 more
doaj  

DOPA‐containing polypeptides. I. Improved synthesis of high‐molecular‐weight poly(L‐DOPA) and water‐soluble copolypeptides [PDF]

, 1978
William D. Fuller, Michael S. Verlander, Murray Goodman   +2 more
openalex   +1 more source

Refractory Motor Complications: Towards a Pragmatic Definition

Movement Disorders Clinical Practice, EarlyView.
Georg Ebersbach, Tobias Warnecke
wiley   +1 more source

Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is a worldwide, complex neurodegenerative disorder influenced by both genetic and environmental factors. Around 15–20% of PD cases are linked to genetic mutations, providing insights into the disease's pathogenesis.
Chiara Meneghini, Luca Gallo, Arianna Sala, Enza Maria Valente, Micol Avenali, Silvia Paola Caminiti   +5 more
wiley   +1 more source

Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit

, 2012
George B. Stefano, Kirk J. Mantione, Milena Králíčková, Radek Ptáček, H. Kuželová, T. Esch, Richard M. Kream   +6 more
openalex   +2 more sources

Differential Progression of Neuroinflammation in Patients with Isolated Rapid‐Eye‐Movement Sleep Behavior Disorder

Movement Disorders, EarlyView.
Abstract Background Neuroinflammation, measured using [11C](R)‐PK11195 positron emission tomography (PET), has been reported in isolated rapid‐eye‐movement sleep behavior disorder (iRBD), but its temporal progression is unknown. Objective The aim was to assess longitudinal progression of neuroinflammation in iRBD patients and its relationship with ...
Andreas Myhre Baun, Alex Iranzo, Miriam Højholt Terkelsen, Rainer Hinz, Morten Gersel Stokholm, Kristian Stær, Mónica Serradel, Marit Otto, Kristina Bacher Svendsen, Alicia Garrido, Dolores Vilas, Arne Møller, Carles Gaig, Eduardo Tolosa, David J. Brooks, Per Borghammer, Simon Fristed Eskildsen, Nicola Pavese   +17 more
wiley   +1 more source

Characteristics of Growth Inhibitory Effect of L-3, 4-Dihydroxyphenylalanine (L-DOPA) on Cucumber Seedlings.

, 1999
Naoko Nakajima, Syuntaro Hiradate, Yoshiharu Fujii   +2 more
openalex   +2 more sources

Selective inhibition of monoamine oxidase type B by MDL 72145 increases the central effects of L‐DOPA without modifying its cardiovascular effects [PDF]

, 1986
John R. Fozard, Michael G. Palfreyman, Marc Robin, Monique Zreika   +3 more
openalex   +1 more source

POLG‐Related Parkinsonism with Good Response to Deep Brain Stimulation

Movement Disorders Clinical Practice, EarlyView.
Evdokia Efthymiou, Fabian Büchele, Sujitha Mahendran, Lennart Stieglitz, Bettina Balint   +4 more
wiley   +1 more source